References
- Velizquez EM, Mendoza S, Hamer T, et al. Met-formin therapy in polycystic ovary syndrome reduces hyperinsulinemia, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43: 647–54
- Diamanti-Kandarakis E, Kouli C, Tsianateli T, et al. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrino11998;138:269–74
- Nesder JE, Jakubowicz DJ, Evans WS, et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syn-drome. N Eng1J Med 1998;338:1876–80
- Velizquez EM, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997;90:392–5
- Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991;229:181–7
- Crave JC, Fimbel S, Lejeune H, et al. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995; 80:2057–62
- Acbay O, Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996;65:946–9
- Ehrmann DA, Cavaghan MK, Imperial J, et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:524–30
- Adams J, Franks S, Pols on DW, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hor-mone. Lancet 1985;2:1375–8
- Matsunaga I, Hata T, Kitao M. Ultrasonographic identification of polycystic ovary. Asia-Oceania J Obstet Gynaecol 1985;11:227–32
- Hatch R, Rosenfield RL, Kim MH, et al. Hirsu-tism: implications, etiology and management. Am J Obstet Gynecol 1981;40:815–30
- Pirwany IR, Yates RWS, Cameron IT, et al. Effects of the insulin-like growth factor I (IGF-I) and IGF binding protein in the pathogenesis of polycystic ovary syndrome. Hum Reprod 1999;14:2963–96
- Taylor AE. Insulin-lowering medication in poly-cystic ovary syndrome. Obstet Gynecol Clin North Am 2000;27:583–95
- Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiroinositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314–20
- Huckabee WE. Lactic acidosis. Am J Cardiol 1963; 12:663–6
- Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxford) 1992;36:105–11
- Despres JP. Health consequences of visceral obesity. Ann Med 2001;33:534–41